Growing hub of European activities
Alnylam Pharmaceuticals, a leading biopharmaceutical company focused on RNA interference (RNAi) therapeutics for genetically defined diseases, has announced the opening of a new office in Amsterdam. The Netherlands will become a growing hub of Alnylam’s European activities, with major investments in technical operations and supply-chain and finance activities, including partnerships with local companies. In addition, the Netherlands will continue to be home to several Phase 3 clinical trial sites across Alnylam’s late-stage assets.
At the heart of innovation
Alnylam Pharmaceuticals was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes featured the company on its list of the 100 most innovative growth companies. The new Amsterdam location was chosen because of the talent, infrastructure, R&D ecosystem and world-class academic hospitals that both the Amsterdam Area and the country have to offer to the life sciences & health sector.
“Vibrant biotech ecosystem”
Alnylam also recognises the Netherlands’ open, collaborative environment, in which highly innovative businesses can thrive. Barry Greene, President of Alnylam Pharmaceuticals, says: “We have identified the Netherlands as a future hub of our European operations. This is testimony to the country’s vibrant biotech ecosystem and to its attractive environment, which makes it possible for companies with groundbreaking innovation to flourish.” Wouter Bos, CEO of Invest NL, adds: “Alnylam Pharmaceuticals’ decision to establish a new office in Amsterdam is a logical one, because we share the same focus on high-quality research. Dutch universities are ranked among the world’s top 2% – an exceptional position.”
The Netherlands’ thriving health sector
With more than 2,900 life sciences and health companies representing 34,000 jobs within a 200km radius, the Netherlands boasts one of the most dense and innovative life sciences ecosystems in the world. The global leader for patent applications in the area of medical technologies, its innovative potential is fuelled by world-class health and research institutes, including 12 research universities, 85 hospitals, including seven University Medical Centres, and more than 200 public-private partnerships between science, industry and government. The country is also a global digital health leader, ranking first in the world in terms of adoption of eHealth solutions in hospitals and clinics.